This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

WCLC, Barcelona, Spain 7-10 September 2019

A Phase IIIb open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: Final analysis

Yi-Long Wu, Haiyan Tu, Jifeng Feng, Meiqi Shi, Jun Zhao, Yuyan Wang, Jianhua Chang, Jialei Wang, Ying Cheng, Jing Zhu, Eng-Huat Tan, Yiping Zhang, Victor Lee, Cheng-Ta Yang, Wu-Chou Su, David Chi-Leung Lam, BJ Srinivasa, Senthil Rajappa, Ching-Liang Ho, Kwok Chi Lam, Yi Hu, Shailesh Arjun Bondarde, Xiaoqing Liu, Kaimin Pang, Yahui Tian, Agnieszka Cseh, Dennis Chin-Lun Huang, Caicun Zhou

wclc_2019_poster_wu_1200.66_final_analysis.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

A Phase IIIb open-label, single-arm study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: An interim analysis

Wu Y-L, et al. WCLC 2017. P3.01-036

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

WCLC 2019

Find information on Boehringer Ingelheim’s activities at WCLC 2019

NSCLC afatinib clinical trials

NSCLC afatinib clinical trials

Afatinib’s Clinical Trials In NSCLC

FOR HEALTHCARE PROFESSIONALS ONLY